S-606001 not checked

Shionogi

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
3 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Pompe Disease (3 trials)
Main trialPhase 2
“The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an add-on to ERT.”In the company’s words, NCT07123155 on ClinicalTrials.gov

Other drugs for Pompe Disease

All 4 drugs for Pompe Disease

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 8 Aug 2027 Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
Phase 2Not yet recruiting 31 Aug 2028 An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)
Phase 1Not yet recruiting 31 Oct 2028 A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow S-606001

Following is part of Solo: you see every change to S-606001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in